Starpharma narrows loss as Genentech deal lifts revenue and new funding extends runway
Melbourne biotech Starpharma grew annual revenue on a Genentech licence payment, cut its loss, and completed a $30 million entitlement offer, giving it cash into 2028 to advance its cancer pipeline.